Search Results - "PECHERSTORFER, M"

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies by BODY, J. J, DIEL, I. J, LICHINITZER, M, LAZAREV, A, PECHERSTORFER, M, BELL, R, TRIPATHY, D, BERGSTROM, B

“…Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for many patients due to…”
Get full text

The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study by Riedl, J., Posch, F., Prager, G., Eisterer, W., Öhler, L., Thamer, S., Wilthoner, K., Petzer, A., Pichler, P., Hubmann, E., Winder, T., Burgstaller, S., Korger, M., Andel, J., Greil, R., Pecherstorfer, M., Philipp-Abbrederis, K., Djanani, A., Gruenberger, B., Längle, F., Wöll, E., Gerger, A.

Get full text

Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine by Eisterer, W., Gerger, A., Öhler, L., Mlineritsch, B., Sliwa, T., Wilthoner, K., Petzer, A., Pichler, P., Hubmann, E., Winder, T., Burgstaller, S., Korger, M., Andel, J., Wöll, E., Neumann, H., Pecherstorfer, M., Philipp-Abbrederis, K., Djanani, A., Gruenberger, B., Längle, F., Prager, G.

Get full text

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate by PECHERSTORFER, M, STEINHAUER, E. U, RIZZOLI, R, WETTERWALD, M, BERGSTRÖM, B

“…To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM). Seventy-two patients with HCM…”
Get full text

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study by von Moos, R., Caspar, C.B., Thürlimann, B., Angst, R., Inauen, R., Greil, R., Bergstrom, B., Schmieding, K., Pecherstorfer, M.

“…Clinical data show that a single, 15-min i.v. infusion of ibandronate 6 mg does not significantly alter renal function. We evaluated the effect on renal…”
Get full text

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy by Pecherstorfer, M, Diel, I J

“…Ibandronate is a third-generation aminobisphosphonate that has an excellent safety record in hypercalcaemia of malignancy, and has recently been approved for…”
Get full text

Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases by Schütz, F, von Moos, R, Caspar, C.B, Angst, R, Inauen, R, Greil, R, Ziegler, J, Pecherstorfer, M

Get full text

Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis by Woitge, Henning W, Horn, Eva, Keck, Andrea V, Auler, Beatrice, Seibel, Markus J, Pecherstorfer, Martin

“…Myeloma-induced bone loss is related to an uncoupling of bone formation and bone resorption. The aim of the present study was to assess the potential clinical…”
Get full text

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy by Pecherstorfer, M, Herrmann, Z, Body, J J, Manegold, C, Degardin, M, Clemens, M R, Thürlimann, B, Tubiana-Hulin, M, Steinhauer, E U, van Eijkeren, M, Huss, H J, Thiébaud, D

“…To evaluate the hypocalcemic effect and safety of three different doses of the bisphosphonate ibandronate in tumor-associated hypercalcemia, and to identify…”
Get more information

Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy by Sauty, A., Pecherstorfer, M., Zimmer-Roth, I., Fioroni, P., Juillerat, L., Markert, M., Ludwig, H., Leuenberger, P., Burckhardt, P., Thiébaudi, D.

“…Bisphosphonates are potent inhibitors of bone resorption and are widely used in the treatment of bone diseases. One of the side effects of administered…”
Get full text

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma by WOITGE, H. W, PECHERSTORFER, M, HORN, E, KECK, A.-V, DIEL, I. J, BAYER, P, LUDWIG, H, ZIEGIER, R, SEIBEL, M. J

“…To test the potential of immunoreactive BSP, a non-collagenous bone matrix component, as a clinical guide in patients with plasma cell dyscrasias, serum BSP…”
Get full text

Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients by Pecherstorfer, M, Schilling, T, Blind, E, Zimmer-Roth, I, Baumgartner, G, Ziegler, R, Raue, F

“…We determined the effect of raised serum levels of midregional (53-84) parathyroid hormone-related protein (PTHrP) on life expectancy in 59 cancer patients…”
Get more information

Cutaneous Melanoma Metastases by Pecherstorfer, Martin

“…Figure 1. In 1990, a 55-year-old woman presented with an acral lentiginous melanoma of the left sole. A radical extirpation of the tumor (tumor stage, T2;…”
Get full text

Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy by Rizzoli, R., Thiébaud, D., Bundred, N., Pecherstorfer, M., Herrmann, Z., Huss, H. J., Rückert, F., Manegold, C., Tubiana-Hulin, M., Steinhauer, E. U., Degardin, M., Thürlimann, B., Clemens, M. R., Eghbali, H., Body, J. J.

“…The pathogenesis of hypercalcemia of malignancy comprises increased net bone resorption and enhanced renal tubular reabsorption of calcium (Ca). To evaluate…”
Get full text

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease by Pecherstorfer, M, Zimmer-Roth, I, Schilling, T, Woitge, H W, Schmidt, H, Baumgartner, G, Thiébaud, D, Ludwig, H, Seibel, M J

“…Bone metastases strongly affect skeletal metabolism by both their growth and their paracrine activities. However, so far no specific laboratory marker has been…”
Get more information

Regional cerebral blood flow in patients suffering from post-traumatic stress disorder by Mirzaei, S, Knoll, P, Keck, A, Preitler, B, Gutierrez, E, Umek, H, Köhn, H, Pecherstorfer, M

“…The aim of the study was to determine whether regional cerebral blood flow in survivors of torture suffering from post-traumatic stress disorder (PTSD)…”
Get more information

Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy by Schilling, T, Pecherstorfer, M, Blind, E, Leidig, G, Ziegler, R, Raue, F

“…We investigated in humoral hypercalcemia of malignancy whether parathyroid hormone-related protein (PTHrP) elevation causes a rise in 1,25-dihydroxyvitamin D…”
Get more information

Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients by ZOJER, N, FIEGL, M, ANGERLER, J, MÜLLAUER, L, GSUR, A, ROKA, S, PECHERSTORFER, M, HUBER, H, DRACH, J

“…In diagnostic evaluation of effusions, difficulties are encountered when atypical reactive mesothelial cells have to be differentiated from malignant cells. We…”
Get full text

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-α-2c in patients with advanced colorectal cancer: final results of a randomised phase III study by Hausmaninger, H, Moser, R, Samonigg, H, Mlineritsch, B, Schmidt, H, Pecherstorfer, M, Fridrik, M, Kopf, Ch, Nitsche, D, Kaider, A, Ludwig, H

“…5-Fluorouracil (5-FU) remains the mainstay of treatment for advanced colorectal carcinoma, although response rates are generally less than 20%. Improved…”
Get full text

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies by Vallet, Sonia, Filzmoser, Julia-Marie, Pecherstorfer, Martin, Podar, Klaus

“…Bone disease, including osteolytic lesions and/or osteoporosis, is a common feature of multiple myeloma (MM). The consequences of skeletal involvement are…”
Get full text